Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:DNLINASDAQ:ELVNNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$32.13+1.4%$39.94$31.67▼$63.46$3.84B0.811.67 million shs2.26 million shsDNLIDenali Therapeutics$14.80+3.0%$14.24$10.57▼$33.33$2.09B1.491.09 million shs1.51 million shsELVNEnliven Therapeutics$19.01+3.2%$19.02$13.30▼$30.03$932.75M1.07261,405 shs473,427 shsPRTAProthena$7.61+2.4%$10.95$6.92▼$25.42$409.62M0.11569,168 shs1.42 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+1.39%-12.38%-16.87%-22.69%-48.26%DNLIDenali Therapeutics+2.85%-7.44%+16.54%-28.09%-19.17%ELVNEnliven Therapeutics+2.70%-6.77%+15.14%-11.21%-18.86%PRTAProthena+2.42%-5.82%-25.54%-44.82%-64.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics4.1393 of 5 stars4.42.00.04.62.40.80.0DNLIDenali Therapeutics3.9234 of 5 stars4.50.00.04.72.01.70.0ELVNEnliven Therapeutics1.7507 of 5 stars3.60.00.00.01.14.20.0PRTAProthena3.2149 of 5 stars4.42.00.00.02.21.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.89Moderate Buy$74.44131.68% UpsideDNLIDenali Therapeutics 3.06Buy$33.79128.28% UpsideELVNEnliven Therapeutics 3.25Buy$40.33112.17% UpsidePRTAProthena 2.75Moderate Buy$51.71579.56% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, PRTA, ELVN, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$48.00 ➝ $30.005/9/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$80.00 ➝ $78.005/9/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/8/2025DNLIDenali TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.005/7/2025CYTKCytokineticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/7/2025DNLIDenali TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/7/2025DNLIDenali TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $32.005/2/2025CYTKCytokineticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.005/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$19.22M199.67N/AN/A($3.94) per share-8.15DNLIDenali Therapeutics$330.53M6.50N/AN/A$7.42 per share1.99ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/APRTAProthena$137.94M2.97N/AN/A$10.46 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%N/ADNLIDenali Therapeutics-$145.22M-$2.67N/AN/AN/AN/A-32.94%-30.04%N/AELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%N/ALatest DNLI, PRTA, ELVN, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ELVNEnliven Therapeutics-$0.51N/AN/AN/AN/AN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million2/27/2025Q4 2024DNLIDenali Therapeutics-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A2/20/2025Q4 2024PRTAProthena-$1.02-$1.08-$0.06-$1.08$7.53 million$2.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokinetics5.939.289.28DNLIDenali TherapeuticsN/A9.989.98ELVNEnliven TherapeuticsN/A17.4417.44PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/ADNLIDenali Therapeutics92.92%ELVNEnliven Therapeutics95.08%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.70%DNLIDenali Therapeutics7.90%ELVNEnliven Therapeutics29.20%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250119.43 million114.00 millionOptionableDNLIDenali Therapeutics430145.28 million132.55 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableDNLI, PRTA, ELVN, and CYTK HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Issues Quarterly Earnings ResultsMay 12 at 11:36 PM | marketbeat.comProthena (NASDAQ:PRTA) Receives "Buy" Rating from Chardan CapitalMay 11 at 8:43 AM | marketbeat.comProthena (NASDAQ:PRTA) Price Target Cut to $78.00 by Analysts at JMP SecuritiesMay 11 at 1:47 AM | americanbankingnews.comProthena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025May 9, 2025 | zacks.comProthena Corporation plc: Prothena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deProthena Corp (PRTA) Sees Price Target Reduction by HC Wainwright & Co. | PRTA Stock NewsMay 9, 2025 | gurufocus.comProthena Corp (PRTA) Sees Price Target Adjusted by JMP Securities | PRTA Stock NewsMay 9, 2025 | gurufocus.comIs Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | msn.comProthena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finance.yahoo.com3PRTA : Beyond The Numbers: 7 Analysts Discuss Prothena Corp StockMay 9, 2025 | benzinga.comTop 3 Health Care Stocks That Are Preparing To Pump This QuarterMay 9, 2025 | benzinga.comAnalysts Set Prothena Co. plc (NASDAQ:PRTA) PT at $55.00May 9, 2025 | americanbankingnews.comProthena (PRTA) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comProthena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2025 | marketbeat.comProthena Q1 2025 Earnings PreviewMay 7, 2025 | msn.comA Look Ahead: Prothena Corp's Earnings ForecastMay 7, 2025 | benzinga.comInsiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458mMay 4, 2025 | finance.yahoo.comBoxer Capital Management LLC Invests $9.56 Million in Prothena Co. plc (NASDAQ:PRTA)May 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases Shares of 80,677 Prothena Co. plc (NASDAQ:PRTA)May 4, 2025 | marketbeat.comWilliam P. Scully Acquires 2,000 Shares of Prothena Co. plc (NASDAQ:PRTA) StockMay 3, 2025 | insidertrades.comPrice T Rowe Associates Inc. MD Trims Holdings in Prothena Co. plc (NASDAQ:PRTA)May 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, PRTA, ELVN, and CYTK Company DescriptionsCytokinetics NASDAQ:CYTK$32.13 +0.44 (+1.39%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$31.96 -0.17 (-0.53%) As of 05/12/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$14.80 +0.43 (+2.99%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$14.94 +0.14 (+0.91%) As of 05/12/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Enliven Therapeutics NASDAQ:ELVN$19.01 +0.59 (+3.20%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$19.01 0.00 (0.00%) As of 05/12/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Prothena NASDAQ:PRTA$7.61 +0.18 (+2.42%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$7.76 +0.15 (+2.04%) As of 05/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
